The DOI matches its OpenAlex record; 49 of the 49 references it cites were found in a registry or an index.
Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects
Open accessAbstract
TGF-betas play diverse and complex roles in many biological processes. In tumorigenesis, they can function either as tumor suppressors or as pro-oncogenic factors, depending on the stage of the disease. We have developed transgenic mice expressing a TGF-beta antagonist of the soluble type II TGF-beta receptor:Fc fusion protein class, under the regulation of the mammary-selective MMTV-LTR promoter/enhancer. Biologically significant levels of antagonist were detectable in the serum and most tissues of this mouse line. The mice were resistant to the development of metastases at multiple organ sites when compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells and in crosses with the MMTV-neu transgenic mouse model of metastatic breast cancer. Importantly, metastasis from endogenous mammary tumors was suppressed without any enhancement of primary tumorigenesis. Furthermore, aged transgenic mice did not exhibit the severe pathology characteristic of TGF-beta null mice, despite lifetime exposure to the antagonist. The data suggest that in vivo the antagonist may selectively neutralize the undesirable TGF-beta associated with metastasis, while sparing the regulatory roles of TGF-betas in normal tissues. Thus this soluble TGF-beta antagonist has potential for long-term clinical use in the prevention of metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manipulating the mouse embryo: A laboratory manual
Hogan, B. L. M., Costantini, F. D., & Lacy, E. (1986) · Cited by 4,460
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,385
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967
Peptide Growth Factors and Their Receptors
Arai, K., Battey, J. F., Sporn, M. B., & Roberts, A. B. (1991) · Medical Entomology and Zoology · Cited by 1,225
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., & Ruoslahti, E. (1990) · Nature · doi:10.1038/346371a0 · Cited by 988
Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., & Ruoslahti, E. (1992) · Nature · doi:10.1038/360361a0 · Cited by 974
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Gorelik, L., & Flavell, R. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80170-3 · Cited by 962
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Peptide Growth Factors and Their Receptors I · doi:10.1007/978-1-4612-3210-0_8 · Cited by 861
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Branton, M. H., & Kopp, J. B. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00250-6 · Cited by 603
Distribution and modulation of the cellular receptor for transforming growth factor-beta.
Wakefield, L. M., Smith, D. M., Masui, T., Harris, C. C., & Sporn, M. B. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.2.965 · Cited by 535
Self-citationRole of Transforming Growth Factor-beta Signaling in Cancer
de Caestecker, M. P. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.17.1388 · Cited by 522
Latent transforming growth factor-β: Structural features and mechanisms of activation
Munger, J. S., Harpel, J. G., Gleizes, P.-E., Mazzieri, R., Nunes, I., & Rifkin, D. B. (1997) · Kidney International · doi:10.1038/ki.1997.188 · Cited by 511
Danielpour, D., Dart, L. L., Flanders, K. C., Roberts, A. B., & Sporn, M. B. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041380112 · Cited by 444
Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116871 · Cited by 359
The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold, L. I. (1999) · PubMed · Cited by 337
Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency
Tang, B., Böttinger, E. P., Jakowlew, S. B., Bagnall, K. M., Mariano, J., Anver, M. R., Letterio, J. J., & Wakefield, L. M. (1998) · Nature Medicine · doi:10.1038/nm0798-802 · Cited by 314
Self-citationLucas, P. J., Kim, S.-J., Melby, S. J., & Gress, R. E. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1187 · Cited by 244
Letterio, J. J., Geiser, A. G., Kulkarni, A. B., Dang, H., Kong, L., Nakabayashi, T., Mackall, C. L., Gress, R. E., & Roberts, A. B. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119017 · Cited by 232
Self-citationEngle, S. J., Hoying, J. B., Boivin, G. P., Ormsby, I., Gartside, P. S., & Doetschman, T. C. (1999) · PubMed · Cited by 216
Pathobiology of the aging mouse
Möhr, U., Dungworth, D. L., & Capen, C. C. (1996) · Medical Entomology and Zoology · Cited by 214
Critical Steps in Hematogenous Metastasis
Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30063-2 · Cited by 210
Dalal, B. I., Keown, P. A., & Greenberg, A. H. (1993) · PubMed · Cited by 208
Kong, F.-M., Anscher, M. S., Murase, T., Abbott, B. D., Iglehart, J. D., & Jirtle, R. L. (1995) · Annals of Surgery · doi:10.1097/00000658-199508000-00007 · Cited by 201
Böttinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K. M., & Wakefield, L. M. (1997) · PubMed · Cited by 196
Self-citationCritical steps in hematogenous metastasis: an overview.
Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001) · PubMed · Cited by 191
Wang, Q., Wang, Y., Hyde, D. M., Gotwals, P. J., Koteliansky, V. E., Ryan, S. T., & Giri, S. N. (1999) · Thorax · doi:10.1136/thx.54.9.805 · Cited by 186
SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-β knockout mice
Dang, H., Geiser, A. G., Letterio, J. J., Nakabayashi, T., Kong, L., Fernandes, G., & Talal, N. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.6.3205 · Cited by 181
Self-citationFueyo, J., Gomez-Manzano, C., Yung, W. K. A., Liu, T. J., Alemany, R., McDonnell, T. J., Shi, X., Rao, J. S., Levin, V. A., & Kyritsis, A. P. (1998) · Nature Medicine · doi:10.1038/nm0698-685 · Cited by 175
Ueno, H., Sakamoto, T., Nakamura, T., Qi, Z., Astuchi, N., Takeshita, A., Shimizu, K., & Ohashi, H. (2000) · Human Gene Therapy · doi:10.1089/10430340050016139 · Cited by 135
Isaka, Y., Akagi, Y., Ando, Y., Tsujie, M., Sudo, T., Ohno, N., Border, W. A., Noble, N. A., Kaneda, Y., Hori, M., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00275.x · Cited by 129
TGF-β in infections and infectious diseases
Reed, S. G. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00252-x · Cited by 125
Reiß, M. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00251-8 · Cited by 120
Amendt, C., Schirmacher, P., Weber, H., & Blessing, M. (1998) · Oncogene · doi:10.1038/sj.onc.1202161 · Cited by 119
Zheng, H., Wang, J., Koteliansky, V., Gotwals, P. J., & Hauer‐Jensen, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.19282 · Cited by 114
Manipulation of TGF-β to control autoimmune and chronic inflammatory diseases
Chen, W., & Wahl, S. M. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00249-x · Cited by 86
Transforming growth factor-β and breast cancer: Mammary gland development
Barcellos‐Hoff, M. H., & Ewan, K. (2000) · Breast Cancer Research · doi:10.1186/bcr40 · Cited by 81
Komesli, S., Vivien, D., & Dutartre, P. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2540505.x · Cited by 69
Wojtowicz‐Praga, S., Verma, U. M., Wakefield, L. M., López-Jamar, J. M. E., Hartmann, D., & Mazumder, A. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199605000-00001 · Cited by 60
Self-citationAberrant TGF-β Production and Regulation in Metastatic Malignancy
SCHWARZ, L. C., Wright, J. A., Gingras, M., Kondaiah, P., Danielpour, D., Pimentel, M., Sporn, M. B., & Greenberg, A. H. (1990) · Growth Factors · doi:10.3109/08977199009108274 · Cited by 58
Soluble cytokine receptors: novel immunotherapeutic agents
Fernandez-Botrán, R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.497 · Cited by 56
Otsuka, T., Jakubczak, J. L., Vieira, W. D., Bottaro, D. P., Breckenridge, D., LaRochelle, W. J., & Merlino, G. T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.6.2055-2065.2000 · Cited by 56
Self-citationTGF-β in the Cardiovascular System
Topper, J. N. (2000) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(00)00061-x · Cited by 48
Hoefer, M., & Anderer, F. A. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01517218 · Cited by 37
Genetic and Immunologic Determinants of Age-Related and Virus-Induced Cardiopathy
Price, P., & Papadimitriou, J. C. (1996) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 3
Cited by
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Metadata
- Authors
- Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., Anver, M. R., Merlino, G. T., & Wakefield, L. M.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2002-06-15
- Volume
- 109
- Issue
- 12
- Pages
- 1607-1615
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2118916648
- Cited by
- 404
- References
- 49
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.